gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · CTMXHealthcarePharmaceuticals

CytomX Therapeutics, Inc. (CTMX)

$2.35+7.80%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$2.28▼ 41.98% in range
Nov 3, 2025Low $2.18 · High $6.75Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

CytomX Therapeutics closed at $2.35 on Nov 4, up 7.80%, 65.2% below its 52-week closing high. Volume of 6.6M shares was 1.65× its 20-day average (above normal).

Split-adjusted performance: -8.2% over one month, -43.1% over six months, -40.2% over one year.

In the quarter ended Jun 30, 2026, revenue was $1.42M, down 92.4% from a year earlier, with a net margin of -1457.4%.

Short interest was 42.8M shares at the Oct 15 settlement, up 4.8% from the prior report (21.4% of float, 13.8 days to cover).

Market cap$512.1M217.9M shares
Revenue · quarter$1.4M−92.4% YoY
Diluted EPS$-0.09—
P/E · TTM—P/S 28.0×
Net margin-1,457.4%Gross 100.0%
Dividend yieldNone
52-week range2.18 – 6.75−65.2% from high
Volume6.6M1.65× 20-day avg
Volatility · 60d69.6%Annualised
Short % of float21.4%13.8 days to cover
Net cash$330.3MCash $330.3M
Next earnings—Not scheduled
Split-adjusted performance
1W −0.4%1M −8.2%3M −30.3%6M −43.1%YTD −44.8%1Y −40.2%3Y +111.7%5Y −57.1%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum31
Revenue growth12
Net margin16
Value (low P/E)—
Size61

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short42.8M+4.8% vs prior
Days to cover13.8Settled Oct 15
% of float21.4%
Short vol. 10d56.4%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
CTMXCytomX Therapeutics$2.35+7.80%−43.1%−92.4%−1457.4%—$512.1M
CBIOCrescent Biopharma$13.82+5.82%−23.5%———$513.4MCompare
FTHFaeth Therapeutics$19.99+1.73%————$516.6MCompare
STTKShattuck Labs$5.15−5.85%−22.9%———$516.9MCompare
CAPRCapricor Therapeutics$8.92+8.25%−74.1%———$518.6MCompare
EOLSEvolus$7.47+1.36%+18.2%+21.2%−9.6%—$493.4MCompare
OVIDOvid Therapeutics$2.74+14.17%−1.4%−88.3%−2047.6%—$535.1MCompare
CLYMClimb Bio$9.33−4.31%−23.6%———$535.9MCompare
MNPRMonopar Therapeutics$72.81+4.18%+14.0%———$488.7MCompare

News about CytomX Therapeutics

All news →
CytomX Therapeutics to Present at Upcoming September Investor ConferencesGlobeNewswire Inc. · Sep 1, 2026NeutralCytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of CancerGlobeNewswire Inc. · Jun 3, 2026▲ PositiveCytomX Therapeutics to Present at Upcoming June Investor ConferencesGlobeNewswire Inc. · May 21, 2026▲ PositiveCytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded WarrantsGlobeNewswire Inc. · Mar 18, 2026▲ Positive

Quick answers

What does CytomX Therapeutics do?
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms.
What is CTMX's market cap?
$512.06M, based on the Nov 4 close of $2.35.
Does CytomX Therapeutics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of CTMX is sold short?
42.8M shares, 21.4% of float, as of Oct 15, 2026.
What sector is CTMX in?
Healthcare, in the Pharmaceuticals industry.

About CytomX Therapeutics

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

HQ: South San Francisco, CA69 employeesListed Oct 8, 2015cytomx.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology